Ductal carcinoma in situ
Jump to navigation
Jump to search
In oncology, ductal carcinoma in situ (DCIS), also called noninfiltrating intraductal carcinoma, is "a noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma."[1]
The importance of DCIS is not clear..[2] However, it may benefit from treatment.[3]
References
- ↑ Anonymous (2023), Ductal carcinoma in situ (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G et al. (2009). "Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.". Ann Intern Med 151 (10): 738-47. DOI:10.1059/0003-4819-151-10-200911170-00010. PMID 19920274. Research Blogging.
- ↑ Cuzick, Jack; Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George (2010). "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial". The Lancet Oncology. DOI:10.1016/S1470-2045(10)70266-7. ISSN 14702045. Retrieved on 2010-12-08. Research Blogging.